Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, randomized, double-blind and adaptive study to evaluate the safety, reactogenicity and explore the immunogenicity of different formulations of the Prophylactic Vaccine Candidates against SARS - CoV - 2, FINLAY- FR-1 and FINLAY- FR-1A (COVID-19). - SOBERANA 01A

Next Previous
X
Search
Trial Profile

Phase I, randomized, double-blind and adaptive study to evaluate the safety, reactogenicity and explore the immunogenicity of different formulations of the Prophylactic Vaccine Candidates against SARS - CoV - 2, FINLAY- FR-1 and FINLAY- FR-1A (COVID-19). - SOBERANA 01A

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FINLAY FR 1 (Primary) ; Adjuvants
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Acronyms SOBERANA 01A

    • Most Recent Events

    • 08 Feb 2022 Status changed from not yet recruiting to recruiting.
    • 08 Feb 2022 Results published in the Vaccine
    • 30 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top